These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30782982)

  • 1. Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
    Ankrom W; Sanchez RI; Yee KL; Fan L; Mitra P; Wolford D; Triantafyllou I; Sterling LM; Stoch SA; Iwamoto M; Khalilieh S
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
    Feng HP; Caro L; Fandozzi C; Chu X; Guo Z; Talaty J; Panebianco D; Dunnington K; Du L; Hanley WD; Fraser IP; Mitselos A; Denef JF; De Lepeleire I; de Hoon JN; Vandermeulen C; Marshall WL; Jumes P; Huang X; Martinho M; Valesky R; Butterton JR; Iwamoto M; Yeh WW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
    Feng HP; Guo Z; Ross LL; Fraser I; Panebianco D; Jumes P; Fandozzi C; Caro L; Talaty J; Ma J; Mangin E; Huang X; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
    J Antimicrob Chemother; 2019 Mar; 74(3):710-717. PubMed ID: 30541077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
    Feng HP; Guo Z; Caro L; Talaty JE; Mangin E; Panebianco D; Fandozzi C; Zhu Y; Marshall W; Huang X; Hanley WD; Jumes P; Valesky R; Martinho M; Butterton JR; Iwamoto M; Yeh WW
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):962-970. PubMed ID: 31173674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants.
    Cheung TT; Yan Chiu JW; Yuen MF; Ling Lam KS; Yung Cheung BM; Feng HP; Yeh WW; Wang J; Li W; Zhao XM; Wang Z; Mu S
    Clin Ther; 2018 May; 40(5):719-732.e1. PubMed ID: 29724498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole.
    Feng HP; Vaddady P; Guo Z; Liu F; Panebianco D; Levine V; Caro L; Butterton JR; Iwamoto M; Yeh WW
    Clin Transl Sci; 2017 Sep; 10(5):360-365. PubMed ID: 28625018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
    Marshall WL; Feng HP; Caro L; Talaty J; Guo Z; Huang X; Panebianco D; Ma J; Mangin E; O'Reilly TE; Butterton JR; Yeh WW
    Eur J Clin Pharmacol; 2017 May; 73(5):593-600. PubMed ID: 28233047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy.
    Feng HP; Guo Z; Caro L; Marshall WL; Liu F; Panebianco D; Vaddady P; Barbour A; Reitmann C; Jumes P; Gilmartin J; Wolford D; Valesky R; Martinho M; Butterton JR; Iwamoto M; Fraser I; Webster L; Yeh WW
    Clin Transl Sci; 2018 Nov; 11(6):562-572. PubMed ID: 30040871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy.
    Feng HP; Guo Z; Caro L; Marshall WL; Liu F; Panebianco D; Vaddady P; Reitmann C; Jumes P; Wolford D; Fraser I; Valesky R; Martinho M; Butterton JR; Iwamoto M; Webster L; Yeh WW
    Clin Transl Sci; 2018 Nov; 11(6):553-561. PubMed ID: 30040872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
    Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
    Caro L; Prueksaritanont T; Fandozzi CM; Feng HP; Guo Z; Wolford D; Panebianco D; Fraser IP; Levine V; Swearingen D; Butterton JR; Iwamoto M; Yeh WW
    Clin Drug Investig; 2021 Feb; 41(2):133-147. PubMed ID: 33527237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
    Alric L; Bonnet D
    Expert Opin Pharmacother; 2016; 17(5):735-42. PubMed ID: 26933896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
    Evon DM; Dong M; Reeve BB; Peter J; Michael L; Lok AS; Nelson DR; Stewart PW
    J Viral Hepat; 2022 Sep; 29(9):795-806. PubMed ID: 35657133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.
    Feng HP; Guo Z; Fandozzi C; Panebianco D; Caro L; Wolford D; Dreyer DP; Valesky R; Martinho M; Rizk ML; Iwamoto M; Yeh WW
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):952-961. PubMed ID: 31173673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection.
    Pijnenburg DWM; van Seyen M; Abbink EJ; Colbers A; Drenth JPH; Burger DM
    J Antimicrob Chemother; 2020 Sep; 75(9):2661-2665. PubMed ID: 32544221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
    Sun HY; Cheng PN; Tseng CY; Tsai WJ; Chiu YC; Young KC
    Gut; 2018 Jul; 67(7):1342-1350. PubMed ID: 28615303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Pharmacokinetics and Drug Interactions of Doravirine.
    Wilby KJ; Eissa NA
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):637-644. PubMed ID: 30047107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir.
    Kiang TKL
    Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):509-531. PubMed ID: 29557529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.
    Khalilieh S; Yee KL; Sanchez R; Stoch SA; Wenning L; Iwamoto M
    Clin Drug Investig; 2020 Oct; 40(10):927-946. PubMed ID: 32816220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.